Mishcon de Reya page structure
Site header
Main menu
Main content section
What will future medicines regulation look like in the UK?

What will future medicines regulation look like in the UK?

DateTimeIn-Person

When: Monday 4 December 2017
6pm for 6:30pm start, followed by a drinks reception at 7:30pm

Where: Africa House, 70 Kingsway,
London, WC2B 6AH (view map)

Following the announcement that the European Medicines Agency will relocate to Amsterdam, join us for a panel discussion on the regulation of medicines in the UK post-Brexit. The UK's Medicines and Healthcare Regulatory Authority is a world respected agency which has previously worked hand-in-hand with the EMA. As the UK seeks to maintain its position at the forefront of R&D and new product launches, how will the MHRA support this, and what is the best possible outcome?

The panel will analyse what ideas for an alternative landscape can be derived from other countries' models, and how best we can leverage our relationship with the EMA going forward.

Panel:

Sir Alasdair Breckenridge - Former Chair, MHRA
Jonathan Mogford - Director of Policy, MHRA
Steve Bates - Chief Executive, BIA
Sarah Rickwood - Vice President, Thought Leadership (Europe), IQVIA

Introduction by:

Rob Murray, Partner - Mishcon de Reya LLP

Chaired by:

Natasha Pearman, Managing Associate - Mishcon de Reya LLP

How can we help you?
Help

How can we help you?

Subscribe: I'd like to keep in touch

If your enquiry is urgent please call +44 20 3321 7000

Crisis Hotline

I'm a client

I'm looking for advice

Something else